HC Wainwright Cuts KalVista Pharmaceuticals (NASDAQ:KALV) Price Target to $20.00

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) had its price target dropped by equities researchers at HC Wainwright from $24.00 to $20.00 in a report issued on Friday, Benzinga reports. The firm currently has a "buy" rating on the specialty pharmaceutical company's stock. HC Wainwright's price objective would suggest a potential upside of 64.88% from the stock's current price.

Separately, Needham & Company LLC reiterated a "buy" rating and issued a $35.00 target price on shares of KalVista Pharmaceuticals in a report on Wednesday.

KalVista Pharmaceuticals Trading Down 0.3 %

KalVista Pharmaceuticals stock traded down $0.04 during mid-day trading on Friday, hitting $12.13. The company's stock had a trading volume of 199,656 shares, compared to its average volume of 697,894. KalVista Pharmaceuticals has a 1 year low of $7.21 and a 1 year high of $16.88. The firm has a market capitalization of $511.76 million, a PE ratio of -3.85 and a beta of 0.92. The stock's fifty day moving average is $12.13 and its two-hundred day moving average is $11.38.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last posted its earnings results on Monday, March 11th. The specialty pharmaceutical company reported ($0.84) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.09). On average, equities analysts expect that KalVista Pharmaceuticals will post -3.05 EPS for the current fiscal year.

Insider Buying and Selling at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, major shareholder Venrock Healthcare Capital Par purchased 4,474 shares of KalVista Pharmaceuticals stock in a transaction dated Tuesday, February 6th. The shares were acquired at an average price of $14.74 per share, with a total value of $65,946.76. Following the completion of the transaction, the insider now owns 4,743,157 shares of the company's stock, valued at $69,914,134.18. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other KalVista Pharmaceuticals news, CEO Thomas Andrew Crockett sold 24,888 shares of the stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $14.11, for a total transaction of $351,169.68. Following the sale, the chief executive officer now directly owns 211,203 shares in the company, valued at approximately $2,980,074.33. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Venrock Healthcare Capital Par bought 4,474 shares of KalVista Pharmaceuticals stock in a transaction on Tuesday, February 6th. The shares were acquired at an average price of $14.74 per share, for a total transaction of $65,946.76. Following the completion of the acquisition, the insider now owns 4,743,157 shares in the company, valued at $69,914,134.18. The disclosure for this purchase can be found here. Insiders sold a total of 75,978 shares of company stock valued at $1,070,918 in the last three months. 12.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On KalVista Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in KALV. Vanguard Group Inc. raised its holdings in shares of KalVista Pharmaceuticals by 9.6% in the 3rd quarter. Vanguard Group Inc. now owns 1,732,489 shares of the specialty pharmaceutical company's stock valued at $16,684,000 after purchasing an additional 151,808 shares in the last quarter. SG Americas Securities LLC raised its holdings in shares of KalVista Pharmaceuticals by 5.1% in the 4th quarter. SG Americas Securities LLC now owns 137,817 shares of the specialty pharmaceutical company's stock valued at $1,688,000 after purchasing an additional 6,670 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in shares of KalVista Pharmaceuticals in the 4th quarter valued at $49,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of KalVista Pharmaceuticals in the 4th quarter valued at $126,000. Finally, New York State Common Retirement Fund raised its holdings in shares of KalVista Pharmaceuticals by 1,860.4% in the 3rd quarter. New York State Common Retirement Fund now owns 9,959 shares of the specialty pharmaceutical company's stock valued at $96,000 after purchasing an additional 9,451 shares in the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.